Cancers, Vol. 12, Pages 117: An Outcome Assessment of a Single Institution ’s Longitudinal Experience with Uveal Melanoma Patients with Liver Metastasis

Cancers, Vol. 12, Pages 117: An Outcome Assessment of a Single Institution’s Longitudinal Experience with Uveal Melanoma Patients with Liver Metastasis Cancers doi: 10.3390/cancers12010117 Authors: Rino S. Seedor David J. Eschelman Carin F. Gonsalves Robert D. Adamo Marlana Orloff Anjum Amjad Erin Sharpe-Mills Inna Chervoneva Carol L. Shields Jerry A. Shields Michael J. Mastrangelo Takami Sato There is no FDA-approved treatment for metastatic uveal melanoma (UM) and overall outcomes are generally poor for those who develop liver metastasis. We performed a retrospective single-institution chart review on consecutive series of UM patients with liver metastasis who were treated at Thomas Jefferson University Hospital between 1971–1993 (Cohort 1, n = 80), 1998–2007 (Cohort 2, n = 198), and 2008–2017 (Cohort 3, n = 452). In total, 70% of patients in Cohort 1 received only systemic therapies as their treatment modality for liver metastasis, while 98% of patients in Cohort 2 and Cohort 3 received liver-directed treatment either alone or with systemic therapy. Median Mets-to-Death OS was shortest in Cohort 1 (5.3 months, 95% CI: 4.2–7.0), longer in Cohort 2 (13.6 months, 95% CI: 12.2–16.6) and longest in Cohort 3 (17.8 months, 95% CI: 16.6–19.4). Median Eye Tx-to-Death OS was shortest in Cohort 1 (40.8 months, 95% CI: 37.1–56.9), and similar in Cohort 2 (6...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research